Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Amarin Pharms Drug Patent Portfolio

Amarin Pharms owns 1 orange book drug protected by 71 US patents Given below is the list of Amarin Pharms's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10278935 Methods of reducing the risk of a cardiovascular event in a subject on statin therapy 28 Jun, 2033
Active
US10278936 Methods of reducing the risk of a cardiovascular event in a subject on statin therapy 28 Jun, 2033
Active
US10278937 Methods of reducing the risk of a cardiovascular event in a subject on statin therapy 28 Jun, 2033
Active
US10383840 Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease 28 Jun, 2033
Active
US10555924 Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease 28 Jun, 2033
Active
US10555925 Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease 28 Jun, 2033
Active
US10568861 Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease 28 Jun, 2033
Active
US10576054 Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease 28 Jun, 2033
Active
US10668042 Methods of reducing the risk of cardiovascular events in a subject 28 Jun, 2033
Active
US10786478 Methods of reducing the risk of cardiovascular events in a subject 28 Jun, 2033
Active
US10792270 Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease 28 Jun, 2033
Active
US10894028 Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease 28 Jun, 2033
Active
US11000499 Methods of reducing the risk of cardiovascular events in a subject 28 Jun, 2033
Active
US11116742 Methods of reducing the risk of cardiovascular events in a subject 28 Jun, 2033
Active
US11298333 Methods of reducing the risk of cardiovascular events in a subject 28 Jun, 2033
Active
US11369582 Methods of reducing the risk of cardiovascular events in a subject 28 Jun, 2033
Active
US9603826 Methods of reducing the risk of a cardiovascular event in a subject on statin therapy 28 Jun, 2033
Active
US9610272 Methods of reducing the risk of a cardiovascular event in a subject on statin therapy 28 Jun, 2033
Active
US9623001 Methods of reducing the risk of a cardiovascular event in a subject on statin therapy 28 Jun, 2033
Active
US9693984 Methods of reducing the risk of a cardiovascular event in a subject on statin therapy 28 Jun, 2033
Active
US9693985 Methods of reducing the risk of a cardiovascular event in a subject on statin therapy 28 Jun, 2033
Active
US9693986 Methods of reducing the risk of a cardiovascular event in a subject on statin therapy 28 Jun, 2033
Active
US9918954 Methods of reducing the risk of a cardiovascular event in a subject on statin therapy 28 Jun, 2033
Active
US10842768 Compositions and methods for lowering triglycerides 15 Jun, 2030
Active
US8410086 Compositions and methods for lowering triglycerides 15 Jun, 2030
Active
US8455472 Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy 15 Jun, 2030
Active
US8669245 Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy 15 Jun, 2030
Active
US8710041 Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy 15 Jun, 2030
Active
US10010517 Stable pharmaceutical composition and methods of using same 29 Apr, 2030
Active
US10265287 Methods of reducing triglycerides and LDL-C 29 Apr, 2030
Active
US10792267 Methods of treating mixed dyslipidemia 29 Apr, 2030
Active
US10842766 Stable pharmaceutical composition and methods of using same 29 Apr, 2030
Active
US10881632 Stable pharmaceutical composition and methods of using same 29 Apr, 2030
Active
US11103477 Stable pharmaceutical composition and methods of using same 29 Apr, 2030
Active
US11154526 Methods of treating mixed dyslipidemia 29 Apr, 2030
Active
US11213504 Stable pharmaceutical composition and methods of using same 29 Apr, 2030
Active
US11717504 Methods of reducing the risk of cardiovascular events in a subject 29 Apr, 2030
Active
US8298554 Stable pharmaceutical composition and methods of using same 29 Apr, 2030
Active
US8445003 Stable pharmaceutical composition and methods of using same 29 Apr, 2030
Active
US8445013 Stable pharmaceutical composition and methods of using same 29 Apr, 2030
Active
US8454994 Stable pharmaceutical composition and methods of using same 29 Apr, 2030
Active
US8501225 Stable pharmaceutical composition and methods of using same 29 Apr, 2030
Active
US8551521 Stable pharmaceutical composition and methods of using same 29 Apr, 2030
Active
US8563608 Methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy 29 Apr, 2030
Active
US8617593 Stable pharmaceutical composition and methods of using same 29 Apr, 2030
Active
US8617594 Stable pharmaceutical composition and methods of using same 29 Apr, 2030
Active
US8618166 Methods of treating mixed dyslipidemia 29 Apr, 2030
Active
US8623406 Stable pharmaceutical composition and methods of using same 29 Apr, 2030
Active
US8642077 Stable pharmaceutical composition and methods of using same 29 Apr, 2030
Active
US8691871 Methods of treating mixed dyslipidemia 29 Apr, 2030
Active
US8703185 Stable pharmaceutical composition and methods of using same 29 Apr, 2030
Active
US8709475 Stable pharmaceutical composition and methods of using same 29 Apr, 2030
Active
US8293727 Methods of treating hypertriglyceridemia 09 Feb, 2030
Active
US8293728 Methods of treating hypertriglyceridemia 09 Feb, 2030
Active
US8314086 Methods of treating hypertriglyceridemia 09 Feb, 2030
Active
US8318715 Methods of treating hypertriglyceridemia 09 Feb, 2030
Active
US8357677 Methods of treating hypertriglyceridemia 09 Feb, 2030
Active
US8367652 Methods of treating hypertriglyceridemia 09 Feb, 2030
Active
US8377920 Methods of treating hypertriglyceridemia 09 Feb, 2030
Active
US8399446 Methods of treating hypertriglyceridemia 09 Feb, 2030
Active
US8415335 Methods of treating hypertriglyceridemia 09 Feb, 2030
Active
US8426399 Methods of treating hypertriglyceridemia 09 Feb, 2030
Active
US8431560 Methods of treating hypertriglyceridemia 09 Feb, 2030
Active
US8440650 Methods of treating hypertriglyceridemia 09 Feb, 2030
Active
US8518929 Methods of treating hypertriglyceridemia 09 Feb, 2030
Active
US8524698 Methods of treating hypertriglyceridemia 09 Feb, 2030
Active
US8546372 Methods of treating hypertriglyceridemia 09 Feb, 2030
Active
US8680144 Methods of treating mixed dyslipidemia 09 Feb, 2030
Active
US9198892 Composition and/or method for preventing onset and/or recurrence of cardiovascular events 25 Sep, 2027
Active
US9700537 Composition for preventing the occurrence of cardiovascular event in multiple risk patient 31 May, 2027
Active
US8188146 Highly purified ethyl EPA and other EPA derivatives 27 Jan, 2020 Expired


Given below is the list of recent legal activities going on the following drug patents of Amarin Pharms.

Activity Date Patent Number
Patent litigations
Maintenance Fee Reminder Mailed
Critical
15 Jul, 2024 US8318715 (Litigated)
Maintenance Fee Reminder Mailed
Critical
08 Jul, 2024 US8314086
Payment of Maintenance Fee, 4th Year, Large Entity 03 Jul, 2024 US10894028
Expire Patent
Critical
01 Jul, 2024 US8188146
Payment of Maintenance Fee, 4th Year, Large Entity 19 Jun, 2024 US10881632
Maintenance Fee Reminder Mailed
Critical
10 Jun, 2024 US8293728 (Litigated)
Maintenance Fee Reminder Mailed
Critical
10 Jun, 2024 US8293727
Payment of Maintenance Fee, 4th Year, Large Entity 08 May, 2024 US10842768
Payment of Maintenance Fee, 4th Year, Large Entity 08 May, 2024 US10842766
Payment of Maintenance Fee, 12th Year, Large Entity 17 Apr, 2024 US8298554
Payment of Maintenance Fee, 4th Year, Large Entity 20 Mar, 2024 US10792267
Payment of Maintenance Fee, 4th Year, Large Entity 20 Mar, 2024 US10792270
Payment of Maintenance Fee, 4th Year, Large Entity 14 Mar, 2024 US10786478
Maintenance Fee Reminder Mailed
Critical
15 Jan, 2024 US8188146
Payment of Maintenance Fee, 4th Year, Large Entity 15 Nov, 2023 US10668042


Amarin Pharms's Drug Patent Litigations

Amarin Pharms's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Nov 30, 2021, against patent number US8642077. The petitioner Hikma Pharmaceuticals USA Inc. et al., challenged the validity of this patent, with Amarin Pharmaceuticals Ireland Limited as the respondent. Click below to track the latest information on how companies are challenging Amarin Pharms's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US8642077 November, 2021 Terminated-Settled
(14 Mar, 2022)
Amarin Pharmaceuticals Ireland Limited Hikma Pharmaceuticals USA Inc. et al.


Amarin Pharms Drug Patents' Oppositions Filed in EPO

Amarin Pharms drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 27, 2014, by Vogelsang-Wenke, Heike. This opposition was filed on patent number EP10704464A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP17187534A Dec, 2021 Cooke, Richard Revoked
EP17187534A Dec, 2021 Hoffman Eitle Patent- und Rechtsanwälte Partnerschaftsgesellschaft mbB Revoked
EP17187534A Nov, 2021 ELKINGTON AND FIFE LLP Revoked
EP17206714A Sep, 2021 Hoffmann Eitle Granted and Under Opposition
EP17206714A Sep, 2021 Cooke, Richard Granted and Under Opposition
EP17206714A Sep, 2021 ELKINGTON AND FIFE LLP Granted and Under Opposition
EP17168056A Jun, 2021 ELKINGTON AND FIFE LLP Revoked
EP13156122A Aug, 2020 Hoffmann Eitle Revoked
EP16152447A Aug, 2020 Hoffmann Eitle Revoked
EP16152447A Aug, 2020 ELKINGTON AND FIFE LLP Revoked
EP13156122A Aug, 2020 ELKINGTON AND FIFE LLP Revoked
EP10704464A Feb, 2014 Sandoz AG Revoked
EP10704464A Feb, 2014 Vogelsang-Wenke, Heike Revoked


Amarin Pharms's Family Patents

Amarin Pharms drugs have patent protection in a total of 44 countries. It's US patent count contributes only to 35.8% of its total global patent coverage. 6 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Amarin Pharms Drug List

Given below is the complete list of Amarin Pharms's drugs and the patents protecting them.


1. Vascepa

Vascepa is protected by 71 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10278935 Methods of reducing the risk of a cardiovascular event in a subject on statin therapy 28 Jun, 2033
(8 years from now)
Active
US10278936 Methods of reducing the risk of a cardiovascular event in a subject on statin therapy 28 Jun, 2033
(8 years from now)
Active
US10278937 Methods of reducing the risk of a cardiovascular event in a subject on statin therapy 28 Jun, 2033
(8 years from now)
Active
US10383840 Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease 28 Jun, 2033
(8 years from now)
Active
US10555924 Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease 28 Jun, 2033
(8 years from now)
Active
US10555925 Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease 28 Jun, 2033
(8 years from now)
Active
US10568861 Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease 28 Jun, 2033
(8 years from now)
Active
US10576054 Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease 28 Jun, 2033
(8 years from now)
Active
US10668042 Methods of reducing the risk of cardiovascular events in a subject 28 Jun, 2033
(8 years from now)
Active
US10786478 Methods of reducing the risk of cardiovascular events in a subject 28 Jun, 2033
(8 years from now)
Active
US10792270 Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease 28 Jun, 2033
(8 years from now)
Active
US10894028 Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease 28 Jun, 2033
(8 years from now)
Active
US11000499 Methods of reducing the risk of cardiovascular events in a subject 28 Jun, 2033
(8 years from now)
Active
US11116742 Methods of reducing the risk of cardiovascular events in a subject 28 Jun, 2033
(8 years from now)
Active
US11298333 Methods of reducing the risk of cardiovascular events in a subject 28 Jun, 2033
(8 years from now)
Active
US11369582 Methods of reducing the risk of cardiovascular events in a subject 28 Jun, 2033
(8 years from now)
Active
US9603826 Methods of reducing the risk of a cardiovascular event in a subject on statin therapy 28 Jun, 2033
(8 years from now)
Active
US9610272 Methods of reducing the risk of a cardiovascular event in a subject on statin therapy 28 Jun, 2033
(8 years from now)
Active
US9623001 Methods of reducing the risk of a cardiovascular event in a subject on statin therapy 28 Jun, 2033
(8 years from now)
Active
US9693984 Methods of reducing the risk of a cardiovascular event in a subject on statin therapy 28 Jun, 2033
(8 years from now)
Active
US9693985 Methods of reducing the risk of a cardiovascular event in a subject on statin therapy 28 Jun, 2033
(8 years from now)
Active
US9693986 Methods of reducing the risk of a cardiovascular event in a subject on statin therapy 28 Jun, 2033
(8 years from now)
Active
US9918954 Methods of reducing the risk of a cardiovascular event in a subject on statin therapy 28 Jun, 2033
(8 years from now)
Active
US10842768 Compositions and methods for lowering triglycerides 15 Jun, 2030
(5 years from now)
Active
US8410086 Compositions and methods for lowering triglycerides 15 Jun, 2030
(5 years from now)
Active
US8455472 Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy 15 Jun, 2030
(5 years from now)
Active
US8669245 Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy 15 Jun, 2030
(5 years from now)
Active
US8710041 Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy 15 Jun, 2030
(5 years from now)
Active
US10010517 Stable pharmaceutical composition and methods of using same 29 Apr, 2030
(5 years from now)
Active
US10265287 Methods of reducing triglycerides and LDL-C 29 Apr, 2030
(5 years from now)
Active
US10792267 Methods of treating mixed dyslipidemia 29 Apr, 2030
(5 years from now)
Active
US10842766 Stable pharmaceutical composition and methods of using same 29 Apr, 2030
(5 years from now)
Active
US10881632 Stable pharmaceutical composition and methods of using same 29 Apr, 2030
(5 years from now)
Active
US11103477 Stable pharmaceutical composition and methods of using same 29 Apr, 2030
(5 years from now)
Active
US11154526 Methods of treating mixed dyslipidemia 29 Apr, 2030
(5 years from now)
Active
US11213504 Stable pharmaceutical composition and methods of using same 29 Apr, 2030
(5 years from now)
Active
US11717504 Methods of reducing the risk of cardiovascular events in a subject 29 Apr, 2030
(5 years from now)
Active
US8298554 Stable pharmaceutical composition and methods of using same 29 Apr, 2030
(5 years from now)
Active
US8445003 Stable pharmaceutical composition and methods of using same 29 Apr, 2030
(5 years from now)
Active
US8445013 Stable pharmaceutical composition and methods of using same 29 Apr, 2030
(5 years from now)
Active
US8454994 Stable pharmaceutical composition and methods of using same 29 Apr, 2030
(5 years from now)
Active
US8501225 Stable pharmaceutical composition and methods of using same 29 Apr, 2030
(5 years from now)
Active
US8551521 Stable pharmaceutical composition and methods of using same 29 Apr, 2030
(5 years from now)
Active
US8563608 Methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy 29 Apr, 2030
(5 years from now)
Active
US8617593 Stable pharmaceutical composition and methods of using same 29 Apr, 2030
(5 years from now)
Active
US8617594 Stable pharmaceutical composition and methods of using same 29 Apr, 2030
(5 years from now)
Active
US8618166 Methods of treating mixed dyslipidemia 29 Apr, 2030
(5 years from now)
Active
US8623406 Stable pharmaceutical composition and methods of using same 29 Apr, 2030
(5 years from now)
Active
US8642077 Stable pharmaceutical composition and methods of using same 29 Apr, 2030
(5 years from now)
Active
US8691871 Methods of treating mixed dyslipidemia 29 Apr, 2030
(5 years from now)
Active
US8703185 Stable pharmaceutical composition and methods of using same 29 Apr, 2030
(5 years from now)
Active
US8709475 Stable pharmaceutical composition and methods of using same 29 Apr, 2030
(5 years from now)
Active
US8293727 Methods of treating hypertriglyceridemia 09 Feb, 2030
(5 years from now)
Active
US8293728 Methods of treating hypertriglyceridemia 09 Feb, 2030
(5 years from now)
Active
US8314086 Methods of treating hypertriglyceridemia 09 Feb, 2030
(5 years from now)
Active
US8318715 Methods of treating hypertriglyceridemia 09 Feb, 2030
(5 years from now)
Active
US8357677 Methods of treating hypertriglyceridemia 09 Feb, 2030
(5 years from now)
Active
US8367652 Methods of treating hypertriglyceridemia 09 Feb, 2030
(5 years from now)
Active
US8377920 Methods of treating hypertriglyceridemia 09 Feb, 2030
(5 years from now)
Active
US8399446 Methods of treating hypertriglyceridemia 09 Feb, 2030
(5 years from now)
Active
US8415335 Methods of treating hypertriglyceridemia 09 Feb, 2030
(5 years from now)
Active
US8426399 Methods of treating hypertriglyceridemia 09 Feb, 2030
(5 years from now)
Active
US8431560 Methods of treating hypertriglyceridemia 09 Feb, 2030
(5 years from now)
Active
US8440650 Methods of treating hypertriglyceridemia 09 Feb, 2030
(5 years from now)
Active
US8518929 Methods of treating hypertriglyceridemia 09 Feb, 2030
(5 years from now)
Active
US8524698 Methods of treating hypertriglyceridemia 09 Feb, 2030
(5 years from now)
Active
US8546372 Methods of treating hypertriglyceridemia 09 Feb, 2030
(5 years from now)
Active
US8680144 Methods of treating mixed dyslipidemia 09 Feb, 2030
(5 years from now)
Active
US9198892 Composition and/or method for preventing onset and/or recurrence of cardiovascular events 25 Sep, 2027
(2 years from now)
Active
US9700537 Composition for preventing the occurrence of cardiovascular event in multiple risk patient 31 May, 2027
(2 years from now)
Active
US8188146 Highly purified ethyl EPA and other EPA derivatives 27 Jan, 2020
(4 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vascepa's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List